Sanofi

Sanofi-a Ventis Deutschland Gmbh

Walter Kamm

Harald Berchtold

Oliver Bley

Petra Loos

Bernd Bidlingmaier

Verena Siefke-Henzler

Annika Hagendorf

Gerrit Hauck

Julia Schnieders

Isabell Schoettle

Christiane Fuerst

Norbert Nagel

Bruno Baumgartner

Bernd Kuehn

Nino Meyer

Marta Venczel

Till Bussemer

Doris Andert

Ernst-Josef Todt

Bernd Kuhn

The present invention relates to a liquid pharmaceutical composition comprising a peptide of SEQ ID NO.: 2 as an active pharmaceutical ingredient. The composition of the present invention is suitable for medical use in humans, for example in the treatment of disorders of a metabolic syndrome or diabetes or obesity or for reduction of excess food intake.

Liquid pharmaceutical composition

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed.

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives

The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Otamixaban formulations with improved stability

Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives are disclosed.

Stabilized pharmaceutical formulations of insulin aspart are disclosed.

Stabilized pharmaceutical formulations of insulin aspart

Growing community of inventors

Frankfurt am Main, Germany

Walter Kamm